GATUZOSIRAN SODIUM
UNII 68F73249L3

Substance Identification & Data

This profile provides standardized clinical and technical data for Gatuzosiran Sodium, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 68F73249L3.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2409783-35-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

68F73249L3

CAS Registry Number

2409783-35-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

GATUZOSIRAN SODIUM

Official standardized name for this substance within the FDA UNII nomenclature system.

USAN ID

OP-95

Identifier assigned by the United States Adopted Names Council.

Substance Type

Gatuzosiran sodium

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Gatuzosiran Sodium. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Gatuzosiran sodium

Common Names & Synonyms

GATUZOSIRAN SODIUM [USAN]

GSK-4532990A

GSK-4532990B sodium

GSK4532990A

GSK4532990B sodium

RNA, ([1′-de(6-amino-9H-purin-9-yl)]dA-(5′→5′)-sp-Cm-Gm-Um-Am-Am-Gm-Am-Am-(2′-deoxy-2′-fluoro)G-Um-(2′-deoxy-2′-fluoro)C-Um-(2′-deoxy-2′-fluoro)G-Am-Um-Am-Gm-Am-Um-Gm-Am-(3′→3′)-sp-[1′-de(6-amino-9H-purin-9-yl)]dA), 3′-[O-[cis-4-[(3S,8S)-17-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-3,8-bis[[[2-[2-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]amino]carbonyl]-1,6,11-trioxo-15-oxa-2,7,12-triazaheptadec-1-yl]cyclohexyl] hydrogen phosphorothioate] sodium salt, complex with RNA (Um-sp-(2′-deoxy-2′-fluoro)C-sp-Am-sp-(2′-deoxy-2′-fluoro)U-Cm-(2′-deoxy-2′-fluoro)U-Am-Um-Cm-Am-Gm-(2′-deoxy-2′-fluoro)A-Cm-(2′-deoxy-2′-fluoro)U-Um-(2′-deoxy-2′-fluoro)C-Um-(2′-deoxy-2′-fluoro)U-Am-(2′-deoxy-2′-fluoro)C-sp-Gm) sodium salt (1:23:1:20)

all-P-ambo-[(2R,3S)-2-(Hydroxymethyl)oxolan-3-yl] hydrogen 5'-O-({[(2R,3S)-3-({[(cis-4-{(3S,8S)-17-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-3,8-bis[(2-{2-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]ethoxy}ethyl)carbamoyl]-6,11-dioxo-15-oxa-2,7,12-triazaheptadecan-1-oyl}cyclohexyl)oxy]hydroxyphosphorothioyl}oxy)oxolan-2-yl]methoxy}hydroxyphosphorothioyl)-2'-O-methylcytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroguanylyl-(3'→5')-2'-Omethyladenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-Omethylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-Omethylguanylyl-(3'→5')-2'-O-methyl-P-thio-3'-adenylate duplex with all-P-ambo 2'-Omethyl-P-thioguanylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-Omethylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-Omethyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thiouridylyl-(5'→3')-2'-O-methyl-P-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-P-thiocytidylyl-(5'→3')-2'-O-methyluridine sodium salt

External Clinical & Regulatory Resources

Previous UNII68EP8R4PMV

Next UNII68FC4UEX7L